Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Senti Biosciences, Inc.
  6. SocietÓ
    SNTI   US81726A1007

SENTI BIOSCIENCES, INC.

(SNTI)
  Rapporto
Prezzo di chiusura Nasdaq  -  30/11/2022
2.300 USD   +2.22%
10/11Senti Biosciences, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2022
CI
07/10Senti Biosciences, Inc.: Morgan Stanley passa a un giudizio Neutral
MM
29/09Senti Biosciences, Inc.: prospettiva positiva di BofA Securities
MM
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietÓFinanzaConsensusRevisioniFondi 
AttivitÓ
Senti Biosciences Inc., formerly Dynamics Special Purpose Corp., is a pre-clinical biotechnology company. The Company is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. It is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.

Numero di dipendenti : 4 persone.
Vendite per attivitÓ
2021
Contract revenue2.2983%
Grant0.4717%
USD in Milioni
Vendite per regione
2021
United States2.76100%
USD in Milioni
Dirigenti
Nome Titolo EtÓ Da
Timothy K. Lu, Dr. President, Chief Executive Officer & Director 40 2022
Deborah A. Knobelman, Dr. Chief Financial Officer 48 2021
Philip Lee, Dr. Chief Technology Officer 39 2021
Kanya Rajangam, Dr. Chief Medical & Development Officer 47 2022
Amministratori
Nome Titolo EtÓ Da
James J. Collins, Dr. Independent Director 55 2022
Susan D. Berland Independent Director 66 2022
Brenda Cooperstone, Dr. Independent Director 56 2022
Edward T. Mathers Independent Director 61 2022
Omid Farokhzad Independent Director 52 2022
David Epstein Independent Director 59 2022
Timothy K. Lu, Dr. President, Chief Executive Officer & Director 40 2022
Azioni
Voto QuantitÓFlottanteAutocontrolloFlottante totale
Azione A 1 43 386 900 30 157 338 69.5% 0 0.0% 61.4%
Azione B 1 5 750 000 0 0.0% 0 0.0%
Azionisti
NomeAzioni%
NEA Management Co. LLC 4 429 725 10,1%
T. Rowe Price Associates, Inc. (Investment Management) 4 015 483 9,18%
ARK Investment Management LLC 2 087 696 4,77%
Woodline Partners LP 2 000 000 4,57%
D1 Capital Partners LP 1 950 000 4,46%
Redmile Group LLC 1 924 900 4,40%
Timothy K. Lu 1 616 276 3,69%
Sculptor Capital LP 1 540 293 3,52%
Omid Farokhzad 1 431 000 3,27%
Invus Public Equities Advisors LLC 1 055 555 2,41%
Portafoglio di marchi
In collaborazione conAllbrands.markets
Pi¨ marchi di Senti Biosciences, Inc.